每月和每季度一次注射ranibizumab对新生血管性年龄相关性黄斑变性的疗效和安全性评价

• 作 者: 苗媛
• 出 处: 眼科新进展
• 发表日期: 2011年02期
• 关键词: ranibizumab 中心凹 视网膜疾病 choroidal macular degeneration 脉络膜 安全性评价 新生 注射组

目的对中心凹下脉络膜视网膜疾病(choroidal neovascularization,CNV)合并年龄相关性黄斑变性(age-related macular degeneration,AMD)的患者进行每季度一次和每月一次ranibi-zumab注射治疗的非劣效性对比研究。方法初发或再发的中心凹下CNV合并AMD患者353例,

AIM: To compare the non-inferiority of ranibi-zumab injections once per quarter and in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) the study. Methods A total of 353 patients with subfoveal CNV complicated with AMD were enrolled in this study.